Evidence map›Paper›PMID 20875132›Full record

ArticleMolecular cancer2010

The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.

Alicia Arranz, Maria Venihaki, Berber Mol, Ariadne Androulidaki, Erini Dermitzaki, Olga Rassouli, Jorge Ripoll, Efstathios N Stathopoulos, Rosa P Gomariz, Andrew N Margioris and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Effect of chronic stress on tumorigenesis and development.Cellular and molecular life sciences : CMLS · 2022
    Review
  5. Article
  6. Article
  7. Chronic Stress Promotes Cancer Development.Frontiers in oncology · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2014
    Article
  12. Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Alicia ArranzDepartment of Clinical Chemistry, School Of Medicine, University of Crete, 71003 Heraklion, Greece.
Maria Venihaki
Berber Mol
Ariadne Androulidaki
Erini Dermitzaki
Olga Rassouli
Jorge Ripoll
Efstathios N Stathopoulos
Rosa P Gomariz
Andrew N Margioris
Christos Tsatsanis
University of Crete · GRFoundation for Research and Technology Hellas · GRUniversidad Complutense de Madrid · ES

Funding

Worldwide Cancer Research 07-0072
6 · The paper itself

Abstract

introductionStress has been shown to be a tumor promoting factor. Both clinical and laboratory studies have shown that chronic stress is associated with tumor growth in several types of cancer. Corticotropin Releasing Factor (CRF) is the major hypothalamic mediator of stress, but is also expressed in peripheral tissues. Earlier studies have shown that peripheral CRF affects breast cancer cell proliferation and motility. The aim of the present study was to assess the significance of peripheral CRF on tumor growth as a mediator of the response to stress in vivo.

methodsFor this purpose we used the 4T1 breast cancer cell line in cell culture and in vivo. Cells were treated with CRF in culture and gene specific arrays were performed to identify genes directly affected by CRF and involved in breast cancer cell growth. To assess the impact of peripheral CRF as a stress mediator in tumor growth, Balb/c mice were orthotopically injected with 4T1 cells in the mammary fat pad to induce breast tumors. Mice were subjected to repetitive immobilization stress as a model of chronic stress. To inhibit the action of CRF, the CRF antagonist antalarmin was injected intraperitoneally. Breast tissue samples were histologically analyzed and assessed for neoangiogenesis.

resultsArray analysis revealed among other genes that CRF induced the expression of SMAD2 and β-catenin, genes involved in breast cancer cell proliferation and cytoskeletal changes associated with metastasis. Cell transfection and luciferase assays confirmed the role of CRF in WNT- β-catenin signaling. CRF induced 4T1 cell proliferation and augmented the TGF-β action on proliferation confirming its impact on TGFβ/SMAD2 signaling. In addition, CRF promoted actin reorganization and cell migration, suggesting a direct tumor-promoting action. Chronic stress augmented tumor growth in 4T1 breast tumor bearing mice and peripheral administration of the CRF antagonist antalarmin suppressed this effect. Moreover, antalarmin suppressed neoangiogenesis in 4T1 tumors in vivo.

conclusionThis is the first report demonstrating that peripheral CRF, at least in part, mediates the tumor-promoting effects of stress and implicates CRF in SMAD2 and β-catenin expression.

Indexed as

AnimalsBlotting, WesternBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalCorticotropin-Releasing HormoneFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticMiceMice, Inbred BALB CPyrimidinesPyrrolesRadioimmunoassayantalarminCorticotropin-Releasing HormonePyrimidinesPyrroles

Identifiers

PMID20875132
PMCPMC2956730
OpenAlexW2116390790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.